EP Patent

EP0797991A1 — Extended release formulation containing venlafaxine

Assigned to Wyeth · Expires 1997-10-01 · 29y expired

What this patent protects

This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more …

USPTO Abstract

This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of nausea and vomiting than the conventional tablets.

Drugs covered by this patent

Patent Metadata

Patent number
EP0797991A1
Jurisdiction
EP
Classification
—
Expires
1997-10-01
Drug substance claim
No
Drug product claim
No
Assignee
Wyeth
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.